Photo illustration of Wegovy and a weight scale. Wegovy is an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical ...

Key Points Interested in Hims & Hers Health, Inc.? Here are five stocks we like better. Hims & Hers Health plans to acquire ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Shares of Hims & Hers (NYSE:HIMS) dropped roughly 16% in premarket trading on Tuesday after the company reported an unexpected first-quarter loss, missing Wall Street earnings expectations as weaker ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform, saw its stock surge 8% on Friday, May 30th, following the announcement of a 4% workforce reduction. This adjustment comes as the company adapts ...

Throughout 2024, Hims & Hers demonstrated consistent top-line acceleration driven by new product introductions and broader consumer adoption. The company’s revenue grew from $260 million in Q1 2024 to ...

Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 17 cents ...

Hims & Hers built massive weight-loss markets using telehealth. Peptides, if authorized by the FDA, stand to become a major ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer ...